Biophysical methods in drug discovery from small molecule to pharmaceutical

Methods in Molecular Biology

Volumn 1008, Issue , 2013, Pages 327-355

  Holdgate, Geoffrey ^a   Geschwindner, Stefan ^b   Breeze, Alex ^a   Davies, Gareth ^a   Colclough, Nicola ^a   Temesi, David ^a   Ward, Lara ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Calorimetry; Kinetics; Orthogonal screening; Plasma protein binding; SAR by NMR; Surface plasmon resonance; Thermal shift; Thermodynamics

Indexed keywords

ACTIVE TRANSPORT; ARTICLE; ARTIFACT; BINDING AFFINITY; BIOPHYSICS; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BINDING SITE; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG METABOLISM; FOLLOW UP; HIGH THROUGHPUT SCREENING; IC 50; INTERNALIZATION; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; MASS SPECTROMETRY; MOLECULAR RECOGNITION; NUCLEAR MAGNETIC RESONANCE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; PROTEIN INTAKE; PROTEIN NUCLEIC ACID INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; STOICHIOMETRY; SURFACE PLASMON RESONANCE; BINDING SITE; CALORIMETRY; CHEMISTRY; HUMAN; KINETICS; MOLECULAR LIBRARY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN CONFORMATION; STEREOISOMERISM; THERMODYNAMICS;

MOLECULAR LIBRARY; NUCLEIC ACID; PROTEIN; PROTEIN BINDING;

BINDING SITES; CALORIMETRY; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; NUCLEIC ACIDS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEINS; SMALL MOLECULE LIBRARIES; STEREOISOMERISM; SURFACE PLASMON RESONANCE; THERMODYNAMICS;

EID: 84925559033     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-398-5_12     Document Type: Article

References (97)

1. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 8:711-715
2. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1:727-730
3. Edfeldt FBN, Folmer RHA, Breeze AL (2011) Fragment screening to predict druggability (ligandability) and lead discovery success. Drug Discov Today 16:284-287
4. Pérot S et al (2010) Druggable pockets and binding site centric chemical space: A paradigm shift in drug discovery. Drug Discov Today 15:656-667
5. Egner U, Hillig RC (2008) A structural biology view of target druggability. Expert Opin Drug Discov 3:391-401
6. Hajduk PJ, Huth JR, Tse C (2005) Predicting protein druggability. Drug Discov Today 10:1675-1682
7. Cheng AC et al (2007) Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 25:71-75
8. Hajduk PJ, Huth JR, Fesik SW (2005) Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 48:2518-2525
9. Fink T, Reymond JL (2007) Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: Assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. J Chem Inf Model 47:342-353
10. Medina-Franco JL et al (2007) A similaritybased data-fusion approach to the visual characterization and comparison of compound databases. Chem Biol Drug Des 70:393-412
11. Vivat Hannah V et al (2010) Native MS: An ESI way to support structure-And fragmentbased drug discovery. Future Med Chem 2:35-50
12. Copeland R (2003) A mechanistic considerations in high-Throughput screening. Anal Biochem 320:1-12
13. Campos-Olivas R (2010) NMR screening and hit validation in fragment-based drug discovery. Curr Top Med Chem 11:43-67
14. PellecchiaMet al (2008) Perspectives on NMR in drug discovery: A technique comes of age. Nat Rev Drug Discov 7:738-745
15. Billeter M, Wagner G, Wuthrich K (2008) Solution NMR structure determination of proteins revisited. J Biomol NMR 42:155-158
16. Seidler J et al (2003) Identification and prediction of promiscuous aggregating inhibitors among known drugs. J Med Chem 46:4477-4486
17. Dalvit C et al (2000) Identification of compounds with binding affinity to proteins via magnetisation transfer from bulk water. J Biomol NMR 18:65-68
18. Mayer M, Meyer B (1999) Characterisation of ligand binding by saturation transfer difference NMR spectroscopy. Angew Chem Int 38:1784-1788
19. Hajduk PJ, Olejniczak ET, Fesik SW (1997) One-dimensional relaxation-And diffusionedited NMR methods for screening compounds that bind to macromolecules. J Am Chem Soc 119:12257-12261
20. Shuker SB et al (1996) Discovering highaffinity ligands for proteins: SAR by NMR. Science 274:1531-1534
21. Ludwig C, Guenther UL (2009) Ligand-based NMR methods for drug discovery. Front Biosci 14:4565-4574
22. Vanwetswinkel S et al (2005) TINS, target immobilised NMR screening: An efficient and sensitive method for ligand discovery. Chem Biol 12:207-216
23. Dalvit C et al (2005) Sensitivity improvement in 19F NMR-based screening experiments: Theoretical considerations and experimental applications. J Am Chem Soc 127:13380-13385
24. Jahnke W, Rudisser S, Zurini M (2001) Spin label enhanced NMR screening. J Am Chem Soc 123:3149-3150
25. Moy FJ et al (2010) Novel synthesis and structural characterisation of a high-Affinity paramagnetic kinase probe for the identification of non-ATP site binders by nuclear magnetic resonance. J Med Chem 53:1238-1249
26. Becattini B et al (2006) Structure-Activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid. Proc Natl Acad Sci U S A 103:12602-12606
27. Sledz P et al (2010) Optimization of the interligand Overhauser effect for fragment linking: Application to inhibitor discovery against Mycobacterium tuberculosis pantothenate synthetase. J Am Chem Soc 132:4544-4545
28. DanielsonUH(2009) Fragment library screening and lead characterization using SPR biosensors. Curr TopMed Chem 9:1725-1735
29. Huber W, Mueller F (2006) Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology. Curr Pharm Des 12:3999-4021
30. Mukundan H (2009) Waveguide-based biosensors for pathogen detection. Sensors 9:5783-5809
31. Fang Y et al (2006) Resonant waveguide grating biosensor for living cell sensing. Biophys J 91:1925-1940
32. Cunningham BT (2004) Label-free assays on the BIND system. J Biomol Screen 9:481-490
33. Dodgson K et al (2009) 100K well screen for a muscarinic receptor using the Epic label-free system-A reflection on the benefits of the label-free approach to screening seventransmembrane receptors. J Recept Signal Transduct Res 29:163-172
34. Chan LL et al (2009) A method for identifying small molecule aggregators using photonic crystal biosensor microplates. Conf Proc IEEE Eng Med Biol Soc 2009:788-791
35. Heeres JT et al (2009) Identifying modulators of protein-protein interactions using photonic crystal biosensors. J Am Chem Soc 131:18202-18203
36. Chan LL et al (2008) A general method for discovering inhibitors of protein-DNA interactions using photonic crystal biosensors. ACS Chem Biol 3:437-448
37. Fenn JB et al (1989) Electrospray ionization for mass spectrometry of large biomolecules. Science 246:64-71
38. Bruylants G, Wouters J, Michaux C (2005) Differential scanning calorimetry in life science: Thermodynamics, stability, molecular recognition and application in drug design. Curr Med Chem 12:2011-2020
39. Zhang R, Monsma F (2010) Fluorescencebased thermal shift assays. Curr Opin Drug Discov Devel 13:389-402
40. Holdgate GA et al (2010) Affinity-based, biophysical methods to detect and analyze ligand binding to recombinant proteins: Matching high information content with high throughput. J Struct Biol 172:142-157
41. Muckenschnabel I et al (2004) SpeedScreen: Label-free liquid chromatography-mass spectrometry-based high-Throughput screening for the discovery of orphan protein ligands. Anal Biochem 324:241-249
42. Patriksson A, Marklund E, Van Der Spoel D (2007) Protein structures under electrospray conditions. Biochemistry 46:933-945
43. Van Den Heuvel RH, Heck AJ (2004) Native protein mass spectrometry: From intact oligomers to functional machineries. Curr Opin Chem Biol 8:519-526
44. Hofstadler SA, Sannes-Lowery KA (2007) Interrogation of noncovalent complexes by ESI-MS: A powerful platform for high throughput Drug discovery. In: Wanner KT, Höfner G (eds) Mass spectrometry in medicinal chemistry, 1st edn. Wiley, Weinheim, pp 321-338
45. Coan KE, Shoichet BK (2008) Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. J Am Chem Soc 130:9606-9612
46. Feng BYet al (2007) A high-Throughput screen for aggregation-based inhibition in a large compound library. J Med Chem 50:2385-2390
47. Achyuthan KE, Whitten DG (2007) Design considerations for high throughput screening and in vitro diagnostic assays. Comb Chem High Throughput Screen 10:399-412
48. Renaud JP, Delsuc MA (2009) Biophysical technique for ligand screening and drug design. Curr Opin Pharmacol 9:622-628
49. Miller JR et al (2010) The use of biochemical and biophysical tools for triage of highthroughput sceening hits-A case study with Escherichia coli phosphopantetheine adenylyltransferase. Chem Biol Drug Des 75:444-454
50. Zhu Z, Cuozo J (2009) High-Throughput affinity-based technologies for small-molecule drug discovery. J Biomol Screen 14:1157-1164
51. Holdgate G (2007) Thermodynamics of binding interactions in the rational drug design process. Expert Opin Drug Discov 2:1103-1114
52. Zehender H et al (2004) SpeedScreen: The missing link between genomics and lead discovery. J Biomol Screen 9:498-505
53. Giannetti AM, Koch BD, Browner MF (2008) Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. J Med Chem 51:574-580
54. Freyer MW, Lewis EA (2008) Isothermal titration calorimetry: Experimental design, data analysis, and probing macromolecule/ligand binding and kinetic interactions. Methods Cell Biol 84:79-113
55. Velazquez-Campoy A et al (2004) Isothermal titration calorimetry. Curr Protoc Cell Biol Chapter 17, Unit 17.8
56. Breeze AL (2000) Isotope-filtered NMR methods for the study of biomolecular structure and interactions. Prog NMR Spectrosc 36:323-372
57. Tugarinov V, Kay LE (2005) Methyl groups as probes of structure and dynamics in NMR studies of high-molecular-weight proteins. Chembiochem 6:1567-1577
58. Li D, DeRose EF, London RE (1999) The inter-ligand Overhauser effect: A powerful new NMR approach for mapping structural relationships of macromolecular ligands. J Biomol NMR 15:71-76
59. Becattini B, Pellecchia M (2006) SAR by ILOEs: An NMR-based approach to reverse chemical genetics. Chem Eur J 12:2658-2662
60. Sanchez-Pedregal VM et al (2005) The INPHARMA method: Protein-mediated interligand NOEs for pharmacophore mapping. Angew Chem Int Ed 44:4172-4175
61. Bartoschek S et al (2010) Drug design for G-protein-coupled receptors by a ligandbased NMR method. Angew Chem Int Ed 49:1426-1429
62. Ladbury JE, Klebe G, Freire E (2010) Adding calorimetric data to decision making in lead discovery: A hot tip. Nat Rev Drug Discov 9:23-27
63. Freire E (2009) A thermodynamic approach to the affinity optimization of drug candidates. Chem Biol Drug Des 74:468-472
64. Ruben AJ, Kiso Y, Freire E (2006) Overcoming roadblocks in lead optimization: A thermodynamic perspective. Chem Biol Drug Des 67:2-4
65. Freire E (2008) Do enthalpy and entropy distinguish first in class from best in class? Drug Discov Today 13:869-874
66. Ferenczy GG, Keseru? GM (2010) Thermodynamics guided lead discovery and optimization. Drug Discov Today 15:919-932
67. Adams H et al (2001) Quantitative determination of intermolecular interactions with fluorinated aromatic rings. Chemistry 7:3494-3503
68. Swinney DC (2009) The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Devel 12:31-39
69. Zhang R, Monsma F (2009) The importance of drug-Target residence time. Curr Opin Drug Discov Devel 12:488-496
70. Tummino PJ, Copeland RA (2008) Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47:5481-5492
71. Copeland RA, Pompliano DL, Meek TD (2006) Drug-Target residence time and its implications for lead optimization. Nat Rev Drug Discov 5:730-739
72. Williams JW, Morrison JF, Duggleby RG (1979) Methotrexate, a high-Affinity pseudosubstrate of dihydrofolate reductase. Biochemistry 18:2567-2573
73. Magotti P et al (2009) Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. J Mol Recognit 22:495-505
74. Lu H et al (2009) Slow-onset inhibition of the FabI enoyl reductase from Francisella tularensis: Residence time and in vivo activity. ACS Chem Biol 4:221-231
75. WanH, RehngrenM(2006) High-Throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectroscopy. J Chromatogr A 1102:125-134
76. Lee KJ et al (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies. Pharm Res 20:1015-1021
77. Rich RL et al (2001) High-resolution and high-Throughput protocols for measuring drug/human serum albumin interactions using biacore. Anal Biochem 296:197-207
78. Valko K et al (2003) Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J Pharm Sci 92:2236-2248
79. Eddershaw PJ, Beresford AP, Baylis MK (2000) ADME/PK as part of a rational approach to drug discovery. Drug Discov Today 5:409-414
80. Hop CE et al (2008) High throughput ADME screening: Practical considerations, impact on the portfolio and enabler of in silico ADME models. Curr Drug Metab 9:847-853
81. Hsieh Y (2008) HPLC-MS/MS in drug metabolism and pharmacokinetic screening. Expert Opin Drug Metab Toxicol 4:93-101
82. Pang KS (2003) Modeling of intestinal drug absorption: Roles of transporters and metabolic enzymes (for the Gillette review series). Drug Metab Dispos 31:1507-1519
83. Muenster U et al (2008) Characterization of substrates and inhibitors for the in vitro assessment of bcrp mediated drug-drug interactions. Pharm Res 25:2320-2326
84. Iwatsubo T et al (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171
85. Prakash C, Shaffer CL, Nedderman A (2007) Analytical strategies for identifying drug metabolites. Mass Spectrom Rev 26:340-369
86. Riley RJ, McGinnity DF, Austin RP (2005) A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304-1311
87. Ito K et al (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol Rev 50:387-412
88. Moody GC et al (1999) Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential. Xenobiotica 29:53-75
89. Trubetskoy OV, Gibson JR, Marks BD (2005) Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J Biomol Screen 10:56-66
90. Zientek M et al (2008) Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. J Pharmacol Toxicol Methods 58:206-214
91. Wang RW et al (2000) Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360-366
92. Grimm SWet al (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: A perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355-1370
93. Atkinson A, Kenny JR, Grime K (2005) Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-Tandem mass spectrometry analysis. Drug Metab Dispos 33:1637-1647
94. Ma B, Prueksaritanont T, Lin JH (2000) Drug interactions with calcium channel blockers: Possible involvement of metaboliteintermediate complexation with CYP3A. Drug Metab Dispos 28:125-130
95. Grime KH et al (2009) Mechanism-based inhibition of cytochrome P450 enzymes: An evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 36:175-191
96. Tiller PR, Romanyshyn LA, Neue UD (2003) Fast LC/MS in the analysis of small molecules. Anal Bioanal Chem 375:788-802
97. Hsieh Y, Korfmacher A (2006) Increasing speed and throughput when using HPLCMS/MS systems for drug metabolism and pharmacokinetic screening. Curr Drug Metab 7:479-489